These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 30285425

  • 1. Endocannabinoid Virodhamine Is an Endogenous Inhibitor of Human Cardiovascular CYP2J2 Epoxygenase.
    Carnevale LN, Arango AS, Arnold WR, Tajkhorshid E, Das A.
    Biochemistry; 2018 Nov 20; 57(46):6489-6499. PubMed ID: 30285425
    [Abstract] [Full Text] [Related]

  • 2. Endocannabinoids anandamide and 2-arachidonoylglycerol are substrates for human CYP2J2 epoxygenase.
    McDougle DR, Kambalyal A, Meling DD, Das A.
    J Pharmacol Exp Ther; 2014 Dec 20; 351(3):616-27. PubMed ID: 25277139
    [Abstract] [Full Text] [Related]

  • 3. Cross-talk of cannabinoid and endocannabinoid metabolism is mediated via human cardiac CYP2J2.
    Arnold WR, Weigle AT, Das A.
    J Inorg Biochem; 2018 Jul 20; 184():88-99. PubMed ID: 29689453
    [Abstract] [Full Text] [Related]

  • 4. The endocannabinoids anandamide and virodhamine modulate the activity of the candidate cannabinoid receptor GPR55.
    Sharir H, Console-Bram L, Mundy C, Popoff SN, Kapur A, Abood ME.
    J Neuroimmune Pharmacol; 2012 Dec 20; 7(4):856-65. PubMed ID: 22454039
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor.
    Porter AC, Sauer JM, Knierman MD, Becker GW, Berna MJ, Bao J, Nomikos GG, Carter P, Bymaster FP, Leese AB, Felder CC.
    J Pharmacol Exp Ther; 2002 Jun 20; 301(3):1020-4. PubMed ID: 12023533
    [Abstract] [Full Text] [Related]

  • 7. Oxidation of the endogenous cannabinoid arachidonoyl ethanolamide by the cytochrome P450 monooxygenases: physiological and pharmacological implications.
    Snider NT, Walker VJ, Hollenberg PF.
    Pharmacol Rev; 2010 Mar 20; 62(1):136-54. PubMed ID: 20133390
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Endocannabinoids and cannabinoid analogues block cardiac hKv1.5 channels in a cannabinoid receptor-independent manner.
    Barana A, Amorós I, Caballero R, Gómez R, Osuna L, Lillo MP, Blázquez C, Guzmán M, Delpón E, Tamargo J.
    Cardiovasc Res; 2010 Jan 01; 85(1):56-67. PubMed ID: 19689982
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Antiangiogenic activity of the endocannabinoid anandamide: correlation to its tumor-suppressor efficacy.
    Pisanti S, Borselli C, Oliviero O, Laezza C, Gazzerro P, Bifulco M.
    J Cell Physiol; 2007 May 01; 211(2):495-503. PubMed ID: 17192847
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Endocannabinoid metabolism by cytochrome P450 monooxygenases.
    Zelasko S, Arnold WR, Das A.
    Prostaglandins Other Lipid Mediat; 2015 May 01; 116-117():112-23. PubMed ID: 25461979
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Endocannabinoids and cannabinoid analogues block human cardiac Kv4.3 channels in a receptor-independent manner.
    Amorós I, Barana A, Caballero R, Gómez R, Osuna L, Lillo MP, Tamargo J, Delpón E.
    J Mol Cell Cardiol; 2010 Jan 01; 48(1):201-10. PubMed ID: 19616555
    [Abstract] [Full Text] [Related]

  • 17. Characterization of the endocannabinoid system in human neuronal cells and proteomic analysis of anandamide-induced apoptosis.
    Pasquariello N, Catanzaro G, Marzano V, Amadio D, Barcaroli D, Oddi S, Federici G, Urbani A, Finazzi Agrò A, Maccarrone M.
    J Biol Chem; 2009 Oct 23; 284(43):29413-26. PubMed ID: 19690173
    [Abstract] [Full Text] [Related]

  • 18. Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells.
    Di Marzo V, Melck D, Orlando P, Bisogno T, Zagoory O, Bifulco M, Vogel Z, De Petrocellis L.
    Biochem J; 2001 Aug 15; 358(Pt 1):249-55. PubMed ID: 11485574
    [Abstract] [Full Text] [Related]

  • 19. A common molecular basis for exogenous and endogenous cannabinoid potentiation of glycine receptors.
    Xiong W, Wu X, Li F, Cheng K, Rice KC, Lovinger DM, Zhang L.
    J Neurosci; 2012 Apr 11; 32(15):5200-8. PubMed ID: 22496565
    [Abstract] [Full Text] [Related]

  • 20. The endocannabinoid anandamide causes endothelium-dependent vasorelaxation in human mesenteric arteries.
    Stanley CP, Hind WH, Tufarelli C, O'Sullivan SE.
    Pharmacol Res; 2016 Nov 11; 113(Pt A):356-363. PubMed ID: 27633407
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.